



Biotech Daily

Wednesday October 21, 2026

Daily news on ASX-listed biotechnology companies

- * ASX, BIOTECH UP: ACTINOGEN UP 12%; SALUDA DOWN 21%
- * AUSBIOTECH 'BIGGEST WEEK IN BIOTECH' BEGINS
- * TELIX 9-MONTH REVENUE UP 21% TO \$1,027m
- * PRO MEDICUS \$43m VIRTUA VISAGE DEAL
- * INVION \$25m POINT8 TRIAL CO-FUNDING RAISE; \$7.5m RDTI LOAN
- * FIREBRICK LAUNCHES NASODINE SINUS RINSE
- * SALUDA: 'FIELD ACTION INVOLVING EVOKE STIMULATOR ISSUES'
- * LTR: 2k DISPENSED SPONTAN FOR ERECTILE DYSFUNCTION
- * GENETIC SIGNATURES, MICROBA AMEND POST-MERGER HOLDINGS
- * CLEO OVARIAN CANCER TEST '75% SENSITIVITY, 100% SPECIFICITY'
- * ONCOSIL 'PANCREATIC CANCER DEVICE 19.8-MONTH MEDIAN SURVIVAL'
- * ACTINOGEN PHASE IIb/III XANAMEM ALZHEIMER'S DATA LOCK
- * PROTEOMICS RECEIVES \$2m FEDERAL R&D TAX INCENTIVE
- * AVECHO PLEADS 'SCHULTZ' TO ASX 35.7% PRICE QUERY
- * ALTERITY M-D DR DAVID STAMLER PAY UP 50% TO \$749k
- * ARCHER 496k EXECUTIVE CHAIR GREGORY ENGLISH RIGHTS AGM
- * HARBOUR ASSET REDUCES TO 9% OF PACIFIC EDGE
- * MARCIN FIREK REPLACES TELIX CO SEC SHOMALIN NAIDOO
- * MATTHEW NG REPLACES HEXIMA DIRECTOR PHILLIP HAINS

MARKET REPORT

The Australian stock market was up 0.16 percent on Wednesday October 21, 2026, with the ASX200 up 14.4 points to 8,831.3 points. Twenty of the Biotech Daily Top 40 companies were up, 11 fell, eight traded unchanged and one was untraded.

Actinogen was the best (see below), up 0.5 cents or 11.6 percent to 4.8 cents, with 10.6 million shares traded; followed by Curvebeam, up 0.2 cents or 11.1 percent to 2.0 cents, with 16.3 million shares traded. Botanix climbed 8.3 percent; Nova Eye was up 7.1 percent; Resonance rose 6.85 percent; Atomo, Avita and Mesoblast were up more than five percent; Artrya and Immutep improved more than four percent; 4D Medical, Alcidion, Compumedics, Dimerix, Imugene, Pro Medicus and Resmed rose two percent or more; Amplia, Cochlear and Nanosonics were up one percent or more; with Clarity, Emvision and Neuren up by less than one percent.

Saluda led the falls (see below), down 7.0 cents or 20.9 percent to 26.5 cents, with 1.5 million shares traded. Cyclopharm, Orthocell and Telix lost more than seven percent; Starpharma fell four percent; EBR was down 3.3 percent; Imricor shed 2.2 percent; Clinuvel, Prescient and Racura were down more than one percent; with CSL and Polynovo down by less than one percent.

AUSBIOTECH

Ausbiotech says 'Australia's Biggest Week in Biotech' including its Ausbiotech Invest, Ausbiotech Conference and Ausmedtech Conference is underway in Queensland.

Ausbiotech said it expected more than 2,500 attendees at the event, which included its three conferences as well as 15 satellite events, six dinners, six workshops and roundtables as well as four site tours and was being held at the Gold Coast Convention and Exhibition Centre in Queensland from October 20 to 23, 2026.

The organization said the event brought "together Australian and international leaders from across biotechnology, medical technology, health technology, research, investment and government for a week of connection, collaboration and partnership".

Ausbiotech said more than 8,600 partnering meetings had been requested, with the week providing "Australia's signature national platform for the life sciences community to exchange knowledge, build relationships and explore opportunities to advance Australian innovation".

The organization said the conference programs included more than 250 speakers in 60 sessions, "exploring the scientific breakthroughs, emerging technologies, investment pathways and partnerships shaping the future of life sciences".

Ausbiotech said the week marked its 40th anniversary, "providing an opportunity to recognize four decades of Australian life sciences innovation and the people, organizations and partnerships that have contributed to the sector's development".

The organization said Ausbiotech Invest was held yesterday and brought investors and six life sciences companies to examine "the financing questions facing Australian companies".

Ausbiotech said the program explored "market conditions, syndication to cross-border capital, and the milestones that shape investment decisions".

Ausbiotech chief executive officer Rebekah Cassidy said that "bringing our flagship conferences together for the first time and partnering across an array of satellite events, we are creating opportunity to strengthen connections across biotechnology, medical technology, health technology, investment and research".

TELEX PHARMACEUTICALS

Telix says revenue for the nine months to September 30, 2026 was up 21.1 percent to \$US722.35 million (\$A1,026.5 million), compared to the prior corresponding period.

Last year, Telix said revenue for the nine months to September 30, 2025 rose 35.4 percent to \$US596.4 million; and earlier this year, said six-month revenue to June 30, 2026 was up 22.3 percent to \$US477.35 million (BD: Oct 15, 2025; Aug 20, 2026).

Today, the company said unaudited revenue for the three months to September 30, 2026 rose 18.9 percent to \$US245 million, "driven by continued strong demand for the commercial portfolio, in line with expectations".

Telix said Precision Medicine revenue for the three months to September 30, 2026 rose 29.7 percent to \$US201 million, mainly from its Illuccix and Gozellix prostate specific membrane antigen (PSMA) positron emission tomography (PET) prostate cancer imaging kits, while manufacturing revenue fell 6.4 percent to \$US44 million.

In 2022, the company said it had US Food and Drug Administration approval for Illuccix; and last year, said the FDA approved Gozellix (BD: Apr 4, 2022; Mar 21, 2025).

Today, Telix said it expected revenue for the year to December 31, 2026 to be "in excess of \$US1 billion, with revenue tracking in line with upper-end of 2025-'26 guidance of \$US950 million to \$US970 million plus \$US40 million of other income".

The company said it had revised expected research and development expenditure for the year to between \$US240 million and \$US260 million, compared to previous guidance of \$US230 million to \$US270 million.

Telix managing-director Dr Chris Behrenbruch said "demand for both Gozellix and Illuccix remained strong during the quarter, with US dose volumes increasing one percent quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality".

"We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base," Dr Behrenbruch said.

Telix fell \$1.24 or 7.9 percent to \$14.52 with five million shares traded.

PRO MEDICUS

Pro Medicus says it has a \$43 million, seven-year contract with the South Jersey, New Jersey-based Virtua Health to provide its Visage 7 medical imaging software.

Pro Medicus said the contract included its Visage 7 Viewer, Visage 7 Workflow, Visage 7 Open Archive and Visage 7 Cardiology Imaging throughout Virtua "providing a single, unified enterprise imaging platform".

The company said it would complete migration from Virtua's legacy picture archiving and communication system (PACS) archives to Visage 7 Open Archive and would also provide enterprise distribution of images integrated to Virtua's electronic health record.

Pro Medicus said Virtua was an academic health system with 3,000 affiliated doctors and clinicians, providing care in five hospitals and was affiliated with the Glassboro, New Jersey-based Rowan University, the University of Pennsylvania Health System (Penn Medicine) and the Children's Hospital of Philadelphia.

The company said implementation was expected about July 2027.

Pro Medicus managing-director Dr Sam Hupert said Virtua joined "an ever-growing list of Visage 7 clients to opt for our fully cloud-based platform, which ... is becoming the standard in the North American healthcare [information technology] market."

"Our pipeline remains strong and spans all market segments," Dr Hupert said.

Pro Medicus was up \$4.90 or 2.7 percent to \$184.83 with 294,173 shares traded.

INVION

Invion says it has an up-to \$25 million, co-funding agreement with Point8 Capital for 11,055,313 options and a \$7.5 million research and development tax incentive loan. Invion executive chair Thian Chew told Biotech Daily the Point8 funds were contingent on Invion matched funds, with Point8 to be paid the 11,055,313 options, pro-rata on the amount raised, but exercisable at 3.639 cents each, regardless of Invion's share price. The company said Sydney's Point8 committed to co-fund its trial program for up-to \$25 million by contributing half of each clinical milestone payment, with the funds to be drawn "in a staged process based on clinical scope and selection".

Invion the options were exercisable within five years from grant, vesting on both a trial candidate reaching phase III development and the funds being provided.

Invion said the Point8 co-funding deed continued until the options lapsed and the facility was fully drawn, repaid or terminated.

The company said it had a \$7.5 million loan from Perth's Rockford Capital, secured against 80 percent of its expected Federal Government Research and Development Tax Incentive for the two years to June 30, 2038.

Invion said the loan would be drawn-down on contract research organization invoice payment dates.

The company said the Rockford Capital loan was at 16.0 percent annual interest, and it would pay a draw-down fee of 1.5 percent of each amount advanced.

Invion said each funding tranche matured "on the earlier of receipt of the refundable [Research and Development] Tax Incentive offset for the income year to which it relates and ... 12 months after the end of that income year, with a final maturity of April 30, 2029".

The company said the funds were for a phase II non-melanoma skin cancer trial, an ano-genital trial with the Peter MacCallum Cancer Centre and other clinical programs.

Invion fell 0.4 cents or 11.1 percent to 3.2 cents.

FIREBRICK PHARMA

Firebrick says it has launched Nasodine Sinus Rinse anti-septic, saline-based nasal and sinus wash kit in Singapore, its third product in the Nasodine range.

Firebrick said nasal and sinus wash products had been used "for some time to provide relief from sinusitis and related conditions" and that its Nasodine Sinus Rinse was "the first product with the germ-killing power of povidone-iodine".

The company said each kit included a sinus rinse bottle and 10 pre-mixed sachets comprising povidone-iodine, as well as salt and xylitol.

Firebrick said the sachets were reconstituted with 200 millilitres of water, as directed, to provide a solution containing 0.1 percent povidone-iodine.

The company said it had completed product manufacturing, and commercial product inventory was available for release to health professionals in Singapore.

Firebrick said the product was available for online purchase on its Singapore website.

Firebrick executive chair Dr Peter Molloy said at low concentrations povidone-iodine was "capable of inactivating the wide range of micro-organisms, bacteria, viruses and fungi, that can be responsible for nasal and sinus infections".

"In Singapore, it will be aimed at hospital and healthcare professionals for a range of clinical uses," Dr Molloy said.

"Nasodine now represents a formidable portfolio of three antiseptic-powered products for use in the upper respiratory tract," Dr Molloy said. "Ultimately, we hope to see all three products in all markets where the nasal spray is sold, including the US."

Firebrick fell 0.2 cents or 6.7 percent to 2.8 cents.

SALUDA MEDICAL

Saluda says it has begun “a voluntary field action” involving some Evoke closed loop stimulators after finding a low-incidence issue relating to third-party manufacturing. Last year, Saluda said it would commercialize its US Food and Drug Administration-approved Evoke spinal cord simulation for pain relief; and last month, said it had FDA approval to market its CAP24 paddle lead (BD: Dec 5, 2025; Jun 30, 2026).

Today, the company said the relevant third-party manufacturing process was corrected, and devices manufactured and distributed following implementation of the corrective action were unaffected by the issue and not included in the affected population.

Saluda said the issue was found “to result in temporary unintended stimulation associated with charging or an inability to charge the implanted device”.

The company said based on the latest information available 26 complaints had been reported among about 3,900 implanted devices within the potentially affected number over a two-year period.

Saluda said based on its statistical projections of remaining implanted patients, “the expected future risk of additional complaints for this issue was about 29 [instances] over the remaining life of the devices”.

The company said it was “not recommending prophylactic replacement or ex-plantation of potentially affected ... devices” and advised continued routine patient management.

Saluda said where the device could not be successfully charged “the physician may determine that device replacement or another intervention is appropriate”.

The company said it would notify physicians and providers, remove and replace potentially affected non-implanted inventory, develop a screening process for non-implanted inventory made prior to the corrective action and engage with US regulators.

Saluda said it did not “expect the action to disrupt product supply or its ability to meet customer demand” or have a material effect on its operations and financial results.

Saluda fell seven cents or 20.9 percent to 26.5 cents with 1.5 million shares traded.

LTR PHARMA

LTR says more than 2,000 Spontan nasal sprays for erectile dysfunction have been dispensed in Australia.

In 2024, LTR said patients had been prescribed its Spontan formulation of vardenafil, marketed as Levitra, under an Australian Therapeutic Goods Administration special access scheme (BD: Aug 16, 2024).

Today, the company said more than 120 clinicians had prescribed Spontan on more than one occasion, dispensing in all six Australian states and the Australian Capital Territory.

LTR said the milestone showed “adoption among Australian clinicians [treating] men whose needs had not been adequately met by existing therapies, including oral [phosphodiesterase type 5] PDE5 therapies (Viagra etc) and injections”.

The company said special access scheme prescriptions of Spontan had “been concentrated in men with moderate or difficult-to-treat erectile dysfunction” including men who had not responded adequately to oral PDE5 inhibitors, such as sildenafil (Viagra) and tadalafil (Cialis) and men with erectile dysfunction following prostate cancer surgery”.

LTR executive chair Lee Rodne said passing 2,000 dispensed units and reaching more than 120 prescribing clinicians were “meaningful milestones for Spontan in Australia”.

“These figures demonstrate demand for an additional treatment option for men with erectile dysfunction, including those who have not responded adequately to oral therapies,” Mr Rodne said.

LTR was up 1.5 cents or 3.2 percent to 48.5 cents.

GENETIC SIGNATURES, MICROBA LIFE SCIENCES

Genetic Signatures and Microba say they have agreed, in principle, for Microba shareholders to hold 60 percent of GSS and current GSS investors to hold 40 percent. Last month, Genetic Signatures (GSS) and Microba announced a merger through a scheme of arrangement with Genetic Signatures to issue Microba about \$39.3 million in scrip (BD: Sep 22, 2026).

At the time, the companies said that following the implementation of the merger, Microba shareholders would hold about 67 percent of Genetic Signatures and existing shareholders would hold about 33 percent, with the company remaining on the ASX under the code GSS.

Today, Genetic Signatures said "all other material terms of the proposed merger remain unchanged" and an addendum to the annual general meeting notice, including an additional resolution to approve the proposed merger, would be released shortly.

The companies did not disclose the reason for the amended terms.

Genetic Signatures was unchanged at 8.4 cents.

Microba fell 0.4 cents or 9.1 percent to four cents.

CLEO DIAGNOSTICS

Cleo says its prototype ovarian cancer screening test "has met or exceeded all pre-defined performance targets" with 75.0 percent sensitivity and 100 percent specificity.

Last month, Cleo said it began prototype development of its multi-biomarker screening blood test for early-stage ovarian cancers in asymptomatic women (BD: Sep 24, 2026).

Today, the company said the results were from a 247-women, first proof-of-concept study which included 87 healthy women, 67 women with benign gynaecological disease and 93 women with ovarian cancer.

Cleo said general population screening showed the test had 75.0 percent sensitivity and 100 percent specificity for stage I cancer detection and 75.8 percent sensitivity and 100 percent specificity for all stages, compared to minimum performance benchmarks of 75.0 percent sensitivity and 99.6 percent specificity.

The company said in the test had 92.2 percent sensitivity and 98.7 percent specificity for stage I cancer detection in the high-risk population, with 90.2 percent sensitivity and 97.4 percent specificity for all-stage cancer detection, compared to a 90 percent benchmark for both sensitivity and specificity.

Cleo said the test "outperformed gold-standard [cancer antigen] CA125 with area under the curve of 0.99 for stage I and 0.98 for all-stage cancers".

The company said the results provided the first evidence that its biomarkers "may have utility in population screening, beyond its lead pre-surgical ovarian cancer test, currently progressing towards [US regulatory] submission early next year".

Cleo said that it would "now advance to the next stage of its screening development pathway, to test the robustness, reproducibility and potential clinical performance of the prototype, including in the low-prevalence setting of general population screening".

Cleo managing-director Dr Richard Allman said the company "set a demanding target before we began, informed by best-practice, precisely so that clearing it would provide meaningful progress".

"Meeting and exceeding those benchmarks for both high-risk and general population screening with a single assay, particularly for early, stage I cancers, the most challenging and clinically important target, gives us confidence that the underlying biology and panel design are sound," Dr Allman said.

Cleo was up one cent or 3.3 percent to 31.5 cents.

ONCOSIL MEDICAL

Oncosil says in 88 patients, the 'Osprey' study shows its pancreatic cancer device with chemotherapy led to median overall survival of 19.8 months from diagnosis.

Last year, Oncosil said data from 64 patients in its 'Osprey' registry study showed its pancreatic cancer device with chemotherapy led to median overall survival of 20.6 months from diagnosis (BD: Dec 3, 2025).

Today, the company said the 19.8-month median overall survival from diagnosis was in patients implanted with its device four months or less from start of first-line chemotherapy, with 25.1-month median overall survival for patients implanted four-to-12 months after starting first-line chemotherapy.

Oncosil said the update results showed "a favorable safety profile, with no grade three or higher or serious adverse device effects reported".

The company said local disease control was reported in 31 of 35 patients implanted within four months of starting chemotherapy and in all 26 patients implanted between four and 12 months after starting chemotherapy.

Oncosil said both evaluable patients implanted after 12 months after starting chemotherapy achieved local disease control.

The company said 10 patients underwent surgical resection with curative intent, with eight patients achieving clear margin resections "highlighting the potential for downstaging to surgery in a proportion of patients".

Oncosil said the 88 patients were treated in 19 centres in Spain, Italy, Greece and Austria. The company said the results were presented at the European Association of Nuclear Medicine Annual Congress 2026 on October 20, 2026 in Vienna, Austria.

Oncosil managing-director Nigel Lange said the "expanded dataset of 88 patients across 19 European centres continues to demonstrate a favorable safety profile and encouraging local disease control".

"These results reinforce the potential role of Oncosil within a multi-disciplinary treatment approach and reflect growing international clinical interest in this targeted therapy," Mr Lange said.

Oncosil fell 1.5 cents or 1.8 percent to 80 cents.

ACTINOGEN MEDICAL

Actinogen says it has completed database lock for its 247-patient, phase IIb/III trial of Xanamem for Alzheimer's disease, with results expected "mid-November".

Last year, Actinogen said all 246 participants were enrolled and had begun treatment in its phase IIb/III trial of Xanamem for Alzheimer's disease (BD: Dec 18, 2025).

Today, the company said database lock was "the point at which the trial data is deemed as entirely final, clean, and locked to further changes".

Actinogen said the final dataset would be "taken by the statistical analysis teams who process the data" before returning the analysis as "topline final results".

Actinogen was up half a cent or 11.6 percent to 4.8 cents with 10.6 million shares traded.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it has received \$2.0 million from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

Proteomics said the incentive related to research and development expenditure for the year to June 30, 2026.

Proteomics was unchanged at 11.5 cents.

AVECHO BIOTECHNOLOGY

Avecho has told the ASX that it is not aware of any information it has not announced which, if known, could explain the recent trading in its securities.

The ASX said the company's share price rose 35.7 percent from a low of 1.4 cents at the close of trading yesterday to a high of 1.9 cents today and noted a "significant increase" in the volume of shares traded.

Avecho was up 0.3 cents or 21.4 percent to 1.7 cents with 15.75 million shares traded.

ALTERITY THERAPEUTICS

Alterity says it has increased managing-director Dr David Stamler's pay by about 49.5 percent from \$A500,746 to \$US525,000 (\$A748,500), effective from October 15, 2026.

Alterity said Dr Stamler would be eligible for a short-term incentive equal to up-to 100 percent of his annual base salary, subject to milestones.

The company said that the increase followed "a review of the remuneration package ... [in which] the directors noted remuneration market comparables, the company's increasing level of activities and the progress of results in line with its objectives".

Alterity did not disclose a reason for the change in currency reported.

Alterity fell 1.5 cents or 5.6 percent to 25.5 cents with 1.3 million shares traded.

ARCHER MATERIALS

Archer says its annual general meeting will vote to issue executive chair Gregory English 496,008 long-term incentive performance rights

Archer said the rights were valued at \$61,009, would vest in three years subject to service, performance, dealing and forfeiture conditions and in addition to Mr English's \$460,720 yearly salary, inclusive of superannuation.

The company said investors would vote to adopt the remuneration report, elect director Andrew Just, issue securities under the performance rights and share option plan and approve potential termination benefits and the 10 percent placement capacity.

The meeting will be held at Stone & Chalk, Level 1, 477 Pitt Street, Sydney on November 20, 2026 at 10.30am (AEDT).

Archer fell half a cent or 2.7 percent to 18 cents.

PACIFIC EDGE

Harbour Asset Management Ltd says it has reduced its substantial shareholding in Pacific Edge from 125,753,262 shares (10.126%) to 113,069,644 shares (9.105%).

The Wellington, New Zealand-based Harbour said that it bought 1,211,048 shares for \$300,535, or 24.8 cents a share, and sold 13,894,666 shares for \$3,502,104, or 25.2 cents a share, but did not disclose the dates of the relevant transactions.

Pacific Edge was up half a cent or 2.7 percent to 19 cents.

HEXIMA

Hexima says it has appointed Matthew Ng as a non-executive director, effective from today, following the resignation of director Phillip Hains.

Hexima was in a suspension and last traded at 1.35 cents.

TELIX PHARMACEUTICALS

Telix says it has appointed Marcin Firek as company secretary, effective from today, to replace interim company secretary Shomalin Naidoo.

In its business update, Telix said Mr Firek had “extensive experience in corporate governance, legal affairs, risk management and public company administration” and had worked for Pricewaterhousecoopers (PWC) Australia, Woolworths Group, ASX Limited and James Hardie Industries.

According to his LinkedIn profile, Mr Firek held a Bachelor of Economics and Bachelor of Laws from Sydney’s Macquarie University.